The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISHL HL Update 2021 | NIVAHL: nivolumab and AVD in early-stage unfavorable HL
Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, outlines results of the NIVAHL trial (NCT03004833), a prospective, randomized Phase II study evaluating nivolumab and doxorubicin, vinblastine, and dacarbazine (AVD) in patients with early-stage unfavorable classical Hodgkin lymphoma (HL). Nivolumab-based first-line treatment led to high remission rates and excellent 12-month progression-free survival and warrants further evaluation in this patient population. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
